Deep Brain Stimulation Shows Promising Results for Stroke Patients

Translate to Spanish or other 102 languages!

Image for Illustration purposes.

Mega Doctor News

- Advertisement -

Cleveland Clinic – Results from a Cleveland Clinic study, which has been years in the making, show the benefits of deep brain stimulation for people who have had a stroke.

Andre Machado, MD, PhD, who is Chairman of the Neurological Institute, helped lead the study.

“We evaluated, for the first time, if we could use a modified type of deep brain stimulation, a modified type of brain pacemaker, going into an area of the brain called the cerebellum, to help people recover from the weakness that resulted from a prior stroke,” explained Dr. Machado.

- Advertisement -

He said 12 patients were involved with the trial and seven of them had a great response, while the other five saw less of an improvement.

For those who did do well, they were able to regain mobility in their hand and arm.

Dr. Machado said they learned during the research that the more residual movement a stroke patient had prior, the better their outcome.

He said there were a lot of amazing stories to come out of the trial, which has been inspiring.

- Advertisement -

“It’s really meaningful for the researchers to see that their work is making a real impact in someone’s life, and it motivates us when a patient tells us that this has been so relevant, so meaningful to me that now I can do this thing that I couldn’t do before. It just makes us work harder,” he said.

Dr. Machado said their research is still far from over. They are getting ready for the next phase of the trial, which will include 40 patients and involvement from other organizations in the United States.

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

DHR Health Raises Over $520K at 20th “Fishing for Hope” Event

DHR Health made a big splash at the 20th Annual “Fishing for Hope” Tournament, held on August 22 at Jim’s Pier in South Padre Island, raising an impressive grand total of $524,130.

FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancer

The U.S. Food and Drug Administration approved Rasonque (daraxonrasib), a RAS inhibitor for the most common form of pancreatic cancer—delivering a new treatment option to patients with advanced pancreatic cancer months ahead of schedule. 

STHS Behavioral Marks Suicide Prevention Month with Community Chalk Event

Every 11 minutes, someone in the United States dies by suicide, according to the Centers for Disease Control and Prevention (CDC), making it one of the nation's leading causes of death.

STHS & Prominence Health Hosting “Senior Living Seminar” on Malnutrition, Sept. 4th

Malnutrition is often an invisible health concern, quietly undermining an older adult's strength, independence and overall quality of life. Yet its warning signs are frequently overlooked or mistaken for a normal part of aging.
- Advertisement -